» Articles » PMID: 21465573

Exploring Genomic Profiles of Hepatocellular Carcinoma

Overview
Journal Mol Carcinog
Date 2011 Apr 6
PMID 21465573
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Gene expression profiling using microarray technologies provides a powerful approach to understand complex biological systems and the pathogenesis of diseases. In the field of liver cancer research, a number of genome-wide profiling studies have been published. These studies have provided gene sets, that is, signature, which could classify tumors and predict clinical outcomes such as survival, recurrence, and metastasis. More recently, the application of genomic profiling has been extended to identify molecular targets, pathways, and the cellular origins of the tumors. Systemic and integrative analyses of multiple data sets and emerging new technologies also accelerate the progress of the cancer genomic studies. Here, we review the genomic signatures identified from the genomic profiling studies of hepatocellular carcinoma (HCC), and categorize and characterize them into prediction, phenotype, function, and molecular target signatures according to their utilities and properties. Our classification of the signatures would be helpful to understand and design studies with extended application of genomic profiles.

Citing Articles

Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.

Foglia B, Sutti S, Cannito S, Rosso C, Maggiora M, Casalino A Front Immunol. 2024; 15:1342404.

PMID: 38469298 PMC: 10925642. DOI: 10.3389/fimmu.2024.1342404.


Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis.

Morine Y, Utsunomiya T, Yamanaka-Okumura H, Saito Y, Yamada S, Ikemoto T Oncotarget. 2022; 13:1286-1298.

PMID: 36441784 PMC: 11623405. DOI: 10.18632/oncotarget.28306.


Associating Preoperative MRI Features and Gene Expression Signatures of Early-stage Hepatocellular Carcinoma Patients using Machine Learning.

Li X, Cheng L, Li C, Hu X, Hu X, Tan L J Clin Transl Hepatol. 2022; 10(1):63-71.

PMID: 35233374 PMC: 8845145. DOI: 10.14218/JCTH.2021.00023.


Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.

Maira G, Foglia B, Napione L, Turato C, Maggiora M, Sutti S J Pathol. 2022; 257(1):82-95.

PMID: 35064579 PMC: 9315146. DOI: 10.1002/path.5871.


Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications.

Raja A, Haq F J Cancer Res Clin Oncol. 2021; 148(1):15-29.

PMID: 34623518 DOI: 10.1007/s00432-021-03826-w.


References
1.
Woo H, Park E, Lee J, Lee Y, Ishikawa T, Kim Y . Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res. 2009; 69(9):4059-66. PMC: 2750086. DOI: 10.1158/0008-5472.CAN-09-0164. View

2.
Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361(15):1437-47. PMC: 2786938. DOI: 10.1056/NEJMoa0901282. View

3.
Farazi P, DePinho R . Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6(9):674-87. DOI: 10.1038/nrc1934. View

4.
Andersen J, Loi R, Perra A, Factor V, Ledda-Columbano G, Columbano A . Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology. 2010; 51(4):1401-9. PMC: 2914300. DOI: 10.1002/hep.23488. View

5.
Minguez B, Tovar V, Chiang D, Villanueva A, Llovet J . Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009; 25(3):186-94. DOI: 10.1097/MOG.0b013e32832962a1. View